Home›Stock Screener›Marksans Pharma

Marksans Pharma Share Price Today | Stock Price & Marksans Pharma Share Screener

MARKSANS Pharmaceuticals & Biotechnology
Live Share Price NSE
₹294.50
▼ -11.60 (-3.79%)
2026-11-18 00:00:00
Live Share Price BSE
₹295.35
▼ -10.45 (-3.42%)
2026-11-18 00:00:00

As of November 18, 2026, the live Marksans Pharma share price (NSE: MARKSANS) is ₹294.50 on NSE and ₹295.35 on BSE, down 3.79% from the previous close, with shares trading between ₹291.30 and ₹315.55 in today's trading session, and a 52-week range of ₹156.89–₹347.60. Track MARKSANS market cap trends to gauge the company's total market size. Use the Marksans Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Marksans Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹958 and net income of ₹144, with EBITDA of ₹232, an operating margin of 23.0% and a profit margin of 15.0%.

Marksans Pharma Market Cap ₹14,437.24 Cr.
MARKSANS P/E Ratio (TTM) 25.60
Marksans Pharma P/B Ratio 4.34
EPS (TTM) ₹9.22
Dividend Yield 0.28%
Debt to Equity 0.12
MARKSANS 52 Week High ₹347.60
Marksans Pharma 52 Week Low ₹156.89
Operating Margin 23.00%
Profit Margin 15.03%
MARKSANS Revenue (TTM) ₹958.00
EBITDA ₹232.00
Net Income ₹144.00
Total Assets ₹3,861.00
Total Equity ₹3,053.00

Marksans Pharma Share Price Chart

Track the current stock price of Marksans Pharma with an interactive chart. Analyse MARKSANS share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Marksans Pharma stock quote in one place.

The quote of ₹294.50 sits between the 52-week low of ₹156.89 and the 52-week high of ₹347.60, and the latest session moved -3.79% from the previous close.

Marksans Pharma Company Profile - Fundamental Screener

Screen Marksans Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for MARKSANS shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE750C01026.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE750C01026

Marksans Pharma Balance Sheet Screener

Screen MARKSANS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹3,861, up from ₹3,240 in 2025.

Latest statistics put total assets at ₹3,861 and shareholder funds at ₹3,053, with a leverage ratio of 0.12.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 3,861 3,240 2,681 2,190 1,640 1,229 903 804 732 752
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 1,044 982 776 486 428 309 303 270 279 267

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 281 273 205 84 61 25 25 18 17 16
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 3,053 2,489 2,086 1,765 1,223 905 649 553 480 440
Share Capital 45 45 45 45 41 41 41 41 41 41
Reserves & Surplus 2,978 2,422 2,020 1,700 1,068 846 595 502 430 393

Marksans Pharma Income Statement Screener - Profit & Revenue Analysis

Screen Marksans Pharma income statement and profit fundamentals. Analyze MARKSANS quarterly results. Marksans Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹958 and net profit was ₹144, equal to earnings per unit of ₹3.12, at an operating margin of 23%.

In that period expenses were ₹726, interest cost ₹7 and tax ₹50. The next period listed, 2026-Jun, shows revenue of ₹866 and net profit of ₹159.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 958 866 891 724 626 742 775 577 606 642 710 497 510 550 591
Expenses 726 628 661 582 520 576 594 450 462 495 543 376 398 417 453

Operating Costs and Margins

EBITDA 232 238 231 142 106 166 181 126 143 147 167 121 112 133 138
Operating Profit % 23.00% 25.00% 23.00% 18.00% 16.00% 20.00% 21.00% 20.00% 22.00% 23.00% 20.00% 23.00% 20.00% 21.00% 23.00%
Depreciation 32 25 24 23 23 27 24 21 20 20 21 14 14 18 22
Interest 7 7 6 3 6 6 6 5 3 3 3 2 2 2 3

Profit and Earnings

Profit Before Tax 194 207 200 116 77 133 151 100 120 125 143 104 97 114 113
Tax 50 47 51 25 18 34 37 23 31 27 38 22 26 30 30
Net Profit 144 159 149 91 58 99 114 78 89 98 105 83 70 84 83
EPS 3.12 3.47 3.27 2.00 1.29 2.17 2.50 1.73 1.96 2.13 2.31 1.97 1.52 1.84 1.84

Marksans Pharma Cash Flow Screener - Liquidity Fundamentals

Screen MARKSANS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹458, and net cash flow was an inflow of ₹138.

Over the same period, investing activities used ₹249 and financing activities used ₹71.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 458 207 230 237 99 179 233 27 50 14
Investing Activities -249 -49 -141 -259 -84 -45 -60 -14 -39 -21

Financing and Net Cash

Financing Activities -71 -65 -69 198 80 -15 -114 -21 3 -4
Net Cash Flow 138 93 21 176 94 119 60 -7 15 -10

Marksans Pharma Shareholding Pattern Screener

See Marksans Pharma shareholding pattern with promoter, FII, and DII holdings. Check Marksans Pharma promoter holding and ownership changes for MARKSANS on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 43.87%, foreign institutions 16.76%, domestic institutions 6.57% and the public 28.33%, spread across 246,279 shareholders.

The shareholder count was 246,279 in 2026-Mar, compared with 246,635 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 43.87% 43.87% 43.87% 43.87% 43.87% 43.87% 43.87% 43.85%

Institutional Investors

FII Holding 16.76% 17.47% 19.06% 22.20% 19.88% 16.92% 8.12% 15.57%
DII Holding 6.57% 6.19% 5.54% 4.56% 5.50% 5.28% 5.91% 5.17%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 28.33% 28.05% 27.05% 25.77% 26.75% 29.53% 28.98% 30.91%
Other Holding 4.45% 4.42% 4.48% 3.59% 4.00% 4.40% 13.11% 4.49%
Shareholder Count 246,279 246,635 247,508 257,273 256,221 265,788 255,153 254,699

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Marksans Pharma. Marksans Pharma dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.90 per unit for 2026-March, a yield of 0.28%, compared with ₹0.80 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.90, ₹0.80 and ₹0.60 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.90 0.28%
2025-March ₹0.80 0.51%
2024-March ₹0.60 0.27%
2023-March ₹0.50 0.33%
2022-March ₹0.25 0.34%
2021-March ₹0.25 0.55%
2020-March ₹0.10 0.20%
2019-March ₹0.05 0.36%
2018-March ₹0.05 0.20%
2017-March ₹0.05 0.16%

Marksans Pharma Stock Index Membership - Nifty & Sensex

See which indices include Marksans Pharma stock. Check MARKSANS index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 5 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP, NIFTY MICROCAP250.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT

Marksans Pharma Market Events Screener - Corporate Actions

Get Marksans Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Marksans Pharma stock events that may affect MARKSANS share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 4, 2026, with a record date of November 4, 2026.

It is followed by Annual General Meeting dated August 27, 2026 and Dividend dated August 20, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-04 2026-11-04 Quarterly Result Announcement NA 1.32%
2026-08-27 2026-08-27 Annual General Meeting NA 23.86%
2026-08-20 2026-08-20 Dividend ₹ 0.90 /share 48.46%
2026-08-12 2026-08-12 Quarterly Result Announcement NA 7.87%
2026-05-26 2026-05-26 Quarterly Result Announcement NA 8.35%
2026-02-05 2026-02-05 Quarterly Result Announcement NA -0.95%
2025-11-13 2025-11-13 Quarterly Result Announcement NA 9.28%
2025-08-12 2025-08-12 Quarterly Result Announcement NA -11.45%
2025-08-08 2025-08-08 Annual General Meeting NA -16.51%
2025-08-01 2025-08-01 Dividend ₹ 0.80 /share -5.63%
2025-05-19 2025-05-19 Quarterly Result Announcement NA 7.03%
2025-02-11 2025-02-11 Quarterly Result Announcement NA 3.18%
2024-11-12 2024-11-12 Quarterly Result Announcement NA 8.46%
2024-09-24 2024-09-24 Annual General Meeting NA 50.49%
2024-09-17 2024-09-17 Dividend ₹ 0.60 /share 73.31%

Marksans Pharma Competitors Screener - Peer Stocks Comparison

Screen MARKSANS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,075 41.20 61,674 12.69% 11,565 63.60
Divis Laboratories 303,749 90.40 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 177,632 85.50 13,886 20.34% 2,138 47.27
Laurus Labs 130,972 97.10 6,868 22.01% 890 69.60
Zydus Life Science 118,693 28.00 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,186 42.00 35,059 3.90% 4,158 70.24
Cipla 112,438 39.90 29,045 2.24% 3,870 54.92
Mankind Pharma 109,044 48.10 14,636 14.85% 1,938 65.43
Aurobindo Pharma 104,903 26.00 34,145 5.56% 3,503 66.06
Lupin 90,557 17.60 29,039 26.75% 5,356 44.92

Marksans Pharma Company Announcements - News & Reports Screener

Screen MARKSANS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 17, 2026.

The next most recent announcements are dated November 9, 2026 and November 9, 2026.

Date Update Actions
2026-11-17 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-09 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-09 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-04 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS -
2026-11-04 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-04 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-04 Financial Results For The Quarter And Half Year Ended 30 September 2026 -
2026-11-04 Board Meeting Outcome for Board Meeting Outcome For Board Meeting Outcome For The Board Meeting Held On 04 November 2026 -
2026-10-26 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-19 Board Meeting Intimation for Declaration Of Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026 -
2026-10-13 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-25 Closure of Trading Window -
2026-09-17 Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares -
2026-09-07 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-01 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-08-27 Voting Results Of The 34Th Annual General Meeting Of The Company -
2026-08-27 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-08-27 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-08-26 Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-08-20 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹294.50, within a 52-week range of ₹156.89 to ₹347.60. The P/E ratio is 25.60 and the P/B ratio is 4.34, with earnings per unit of ₹9.22. Market capitalisation stands at ₹14,437.24 Cr and the dividend yield is 0.28%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.